Genzyme Expands
ePT--the Electronic Newsletter of Pharmaceutical Technology
Cambridge, MA (June 7)-Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.
Cambridge, MA (June 7)-Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.
The company is investing EUR105 million (nearly $140 million) in a new 140,000-ft2 biomanufacturing plant in Lyon, France to replace its smaller plant in nearby Marcy l’Etoile. The new plant, which will be used to manufacture Genzyme’s transplantation treatment “Thymoglobulin,” will have more than twice the manufacturing capacity of the Marcy facility and will create as many as 50 new jobs. The facility’s nine-acre site leaves room for expansion should demand for Thymoglobulin continue to rise.
Genzye also is completing development of a new plant in Belgium, which will be used to produce monoclonal antibodies and proteins. The company intends to expand other facilities, including its Allston Landing protein manufacturing plant in Boston. In addition, a new filling and packaging facility at Genzyme’s manufacturing site in Ireland recently received regulatory approvals.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
